Wright A, Vioix H, de Silva S, Langham S, Cook J, Capstick T, et al. Cost–consequence analysis of COPD treatment according to NICE and GOLD recommendations compared with current clinical practice in the UK. BMJ Open 2022;12(6):e059158.

Sethi S, Wright A, Hartgers-Gubbels E, Hechtner M, Clark B, Wright C, et al. Costs and clinical consequences of compliance with COPD GOLD recommendations or national guidelines compared with current clinical practice in Belgium, Germany, Sweden, and the United States. Int J Chron Obstruct Pulmon Dis 2022;17:2149-2160.

Kriz A, Wright A, Paulsson M, Tomlin S, Simchowitz V, Senterra T, Sheplev J. Cost-consequences analysis of increased utilization of triple-chamber-bag parenteral nutrition in preterm neonates in seven European countries. Nutrients 2020;12(9):2531

Kriz A, Wright A, Paulsson M, Tomlin S, Simchowitz V, Senterra T, Sheplev J. Cost-consequences analysis of increased utilization of triple-chamber-bag parenteral nutrition in preterm neonates in seven European countries. Nutrients 2020;12(9):2531

Wright A, Shepelev J, Kriz A. PAM5 Indirect calorimetry is a cost-saving strategy to manage patients in hospital intensive care. Value Health 2020;23(Suppl 2):S409

Vioix H, Wright A, de Silva S, Langham S, Gayle A, Soto J, Cook J, Capstick T, Quint J. PRS18 The clinical and cost impact of adherence to chronic obstructive pulmonary disease guideline recommendations in England- a cost consequence model. Value Health 2020;23(Suppl 2):S719

Kenworthy J, Langham S, Wright A, Dunlop W. Budget impact analysis of methoxyflurane (Penthrox®) for emergency relief of moderate-to-severe trauma pain in the Swedish setting. Value Health 2018;21(Suppl 3):S443

Langham S, Wright A, Kenworthy J, Grieve R, Dunlop WCN. Cost-effectiveness of take-home naloxone for the prevention of overdose fatalities among heroin users in the UK. Value Health 2018;21(4):407–15. Open access ‘R’ and ‘Excel model’

Kriz A, Migliore A, Wright A, Piaggio T. Modelled effects of a pediatric triple-chamber-bag (3CB) system on payer costs and clinical outcomes in pre-term neonates across France, Germany, and Italy. Value Health 2018;21(Suppl 3): S216–7

Langham S, Wright A, Kenworthy J, Grieve R, Dunlop WCN. Cost-effectiveness of take-home naloxone for the prevention of overdose fatalities among heroin users in the UK. Value Health 2018;21(4):407–15.

Langham S, Wright A, Shaw H, Bryson S, O’Leary S. Budget impact analysis of oral glycopyrronium bromide (Sialanar™) for the symptomatic treatment of severe sialorrhoea (drooling) in the UK setting. Value Health 2017;20(9):A720

Langham S, Kenworthy JJ, Grieve R, Dunlop W. Cost-effectiveness of take-home naloxone for the prevention of fatalities from heroin overdose in the UK. Value Health 2016:19(7):A525–6